Biologics – Page 2 – Pharma.Tips

Biologic sterility assurance gap after equipment qualification update: how to document root cause when multiple unit operations are involved

Identifying the initial signals of a sterility assurance gap is crucial. Symptoms may arise from multiple sources including microbiological testing failures, deviations noted in batch records, or unexpected complaints during…

Biologic hold-time failure for bulk drug substance during tech transfer to a CMO: single-use systems risk controls, leachables review, and supplier oversight actions

When a biologic hold-time failure occurs, the symptoms can emerge at various stages in the production process. Early detection is critical. Here are some common signals you might observe:Click to…

Biologic leachables signal from single-use systems during PPQ / process validation: how to document root cause when multiple unit operations are involved

Symptoms indicating potential biologic leachables from single-use systems might manifest in various ways throughout the manufacturing process. Common indicators include:Click to read the full article.

Biologic upstream yield drop (OOT) during deviation investigation board review: viral safety and contamination response plan with inspection-ready evidence

Identifying symptoms or signals is a critical first step in addressing any production deviation. In the case of a biologic upstream yield drop, tracking various parameters helps in painting a…

Biologic endotoxin OOS during deviation investigation board review: patient safety impact assessment and batch disposition governance

Identifying the initial symptoms or signals that indicate a potential endotoxin OOS result is critical for a timely and effective investigation. The following are common signs to monitor:Click to read…

Biologic leachables signal from single-use systems after upstream media/raw material change: viral safety and contamination response plan with inspection-ready evidence

When issues related to biologic leachables arise, it's crucial to identify early symptoms or signals as they can be indicative of underlying problems with single-use systems or the materials involved…

Biologic sterility assurance gap during CPV trending review: how to document root cause when multiple unit operations are involved

The first step in addressing a biologic sterility assurance gap is recognizing the symptoms or signals that might indicate a problem. These signals may arise from various operational areas, including…

Biologic glycosylation shift (CQAs) outside trend during deviation investigation board review: viral safety and contamination response plan with inspection-ready evidence

Identifying symptoms that indicate a deviation in glycosylation patterns is the first step in the investigation process. Key signals may include:Click to read the full article.

Biologic charge variant shift (CEX) OOS after filling line intervention: patient safety impact assessment and batch disposition governance

The first step in addressing a biologic charge variant shift is to identify the symptoms or signals that alert personnel to potential issues. Common indicators of a CEX OOS incident…

Biologic viral clearance validation gap during stability pull at 3/6/12 months: CAPA package with CQA/CPP risk assessment and effectiveness verification

The first step in any investigation is recognizing the early warning signs that indicate a potential issue. For biologics, the following signals may suggest a viral clearance validation gap:Click to…

Biologic charge variant shift (CEX) OOS after equipment qualification update: viral safety and contamination response plan with inspection-ready evidence

When handling biologics, identifying symptoms on the manufacturing floor or in the laboratory environment is crucial for initiating an appropriate response. For a biologic charge variant shift resulting in an…

Biologic cold chain excursion impact after equipment qualification update: investigation strategy aligned to FDA/EMA expectations and comparability principles

Identifying symptoms indicating a cold chain excursion is the first step in an effective investigation. Signals may arise from both the packaging of biologics and monitoring systems. Key symptoms include:Click…